D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients

September 29th, 2009 GENEVA - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, Merck Serono's proprietary investigational oral formulation of cladribine, as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS). Cladribine Tablets has the potential to be the first orally administered disease-modifying therapy available for people living with relapsing MS, as all disease-modifying therapies currently approved for the treatment of MS are parenteral therapies.

August 16th, 2009 REHOVOT, Israel - D-Pharm announced today the completion of a financial round, which yielded NIS 85 million (approximately $23M USD) to fund the Company's late stage clinical stroke program. The financial round combined a rights offering of NIS 57 million and an Initial Public Offering (IPO) of NIS 28 million.

June 23rd, 2009 MUMBAI, India - Release Highlights - Melogliptin continues to demonstrate potential to be the best-in-class in achieving glycemic control with low incidence of hypoglycemia and neutral effect on body weight - Global Phase III trials likely to start by end 2009 - IND approved by USFDA - Glenmark takes a step closer towards becoming the first Indian company to have a truly global innovative drug for the world In the recently completed 12 week Phase IIb clinical trial in 494 patients with type 2 diabetes mellitus (T2DM), 'Melogliptin', Glenmark's investigational medicine from a new class of diabetes treatments called dipeptidyl peptidase 4 (DPP-4) inhibitors, improved glycemic control in patients with type 2 diabetes mellitus and exhibited excellent safety and tolerability profile. In addition, patients taking Melogliptin experienced low incidence of hypoglycemia and neutral effect on body weight.

June 17th, 2009 SEATTLE, Washington, and LEIDEN, The Netherlands - ProFibrix B.V. today announced the start of the company's Phase II clinical trial for Fibrocaps(TM), the company's lead topical Hemostat product, with the successful treatment of the first patients for mild to moderate bleeding during liver surgery.

May 5th, 2009 STOCKHOLM - Axelar AB today announced successful completion of the single-day oral dosing part of its ongoing phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717,an insulin-like growth factor-1 (IGF-1) receptor inhibitor which has no effects on the closely related insulin receptor. The study is conducted in Sweden on patients having terminal cancer disease.

May 5th, 2009 EVRY, France - Novagali Pharma, a French pharmaceutical ophthalmic company, announces today that the Company's Investigational New Drug Application (IND) to conduct a Phase III clinical trial of Catioprost(R) (Nova21027), for the treatment of glaucoma has been granted by the U.S. Food and Drug Administration (FDA).

April 29th, 2009 CARLSBAD, California - PREPARES FOR LAUNCH OF 'NEST-3' ACUTE ISCHEMIC STROKE CLINICAL TRIAL PhotoThera, Inc., the developer of transcranial laser therapy (TLT) designed for the treatment of acute ischemic stroke within 24 hours of stroke onset, announced today that it has closed a US$50 million Series D round of financing led by Warburg Pincus, a leading global private equity firm, to fund a planned follow-on phase III 'NEST-3' (NeuroThera(R) Effectiveness and Safety Trial) clinical study. The Company previously announced that NEST-3 would build upon the results of its NEST-2 trial, which revealed a statistically significant treatment effect for patients with moderate to moderately severe ischemic strokes using a post-hoc data analysis.

March 23rd, 2009 ABBOTT PARK, Illinois - Abbott (NYSE: ABT) today announced the initiation of the next phase of the ABSORB clinical trial to evaluate the safety and performance of the company's fully bioabsorbable drug eluting coronary stent. This second phase of the ABSORB clinical trial will enroll approximately 80 patients at 10 centers in Europe, Australia and New Zealand, and will incorporate device enhancements designed to improve deliverability and vessel support.

March 11th, 2009 ABBOTT PARK, Illinois - Data Demonstrate Bioabsorbable Stent Is Absorbed Within Two Years, Leaving Behind Blood Vessels that Appear to Move and Function Similar to Untreated Vessels A comprehensive analysis published today in The Lancet, one of the world's leading medical journals, from the ABSORB clinical trial demonstrated that Abbott's bioabsorbable drug eluting stent, currently in development, successfully treated coronary artery disease and was absorbed into the walls of treated arteries within two years. The two-year data also demonstrated that after the bioabsorbable device was absorbed, the treated blood vessels appeared to move and function similar to unstented arteries.

March 11th, 2009 TURKU, Finland - BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun a new Phase IIa clinical testing of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. The double-blind, vehicle-controlled study is designed to evaluate the tolerability, pharmacokinetics, and efficacy of the topical product in a total of 18 subjects with mild to moderate plaque psoriasis.

August 31st, 2009 LONDON - A new drug developed as an alternative to popular drug warfarin, also used as rat poison, has been found to significantly reduce stroke risk. Generally, patients at risk of stroke are given warfarin to prevent blood clotting, but the treatment is risky and requires regular monitoring.

August 30th, 2009 Study shows experimental drug cuts stroke riskBARCELONA, Spain — An experimental drug reduces the stroke risk in patients with irregular heartbeats by nearly four times, compared with the popular drug warfarin — but possibly at a cost, according to new research released Sunday. Patients taking the new drug dabigatran etexilate, made by German pharmaceutical Boehringer Ingelheim, also were slightly more likely to have heart attacks or stomach pain, according to the research presented at the European Society of Cardiology meeting in Barcelona.

April 16th, 2009 WASHINGTON - A stroke patient intravenously received his own bone marrow stem cells, as part of a new research trial in the US. Roland Henrich, 61, was transferred to Memorial Hermann, Texas University Medical Centre (TUMC) on March 25 after suffering a stroke on his farm in Liberty.

September 30th, 2009 WASHINGTON - A new drug has been found to be safer than warfarin (also commonly used in rat poison) for reducing stroke risk, according to a review. Generally, patients at risk of stroke are given warfarin to prevent blood clotting, but the treatment is risky and requires regular monitoring.

October 1st, 2009 Catalyst plans more tests of anti-addiction drugNEW YORK — Catalyst Pharmaceutical Partners Inc. says it will continue developing an anti-addiction drug that has failed in two clinical trials, as it believes the treatment is safe and effective.

June 23rd, 2009 Wife: Astor's 85-year-old son had mild strokeNEW YORK — The wife of Brooke Astor's son, Anthony Marshall, says her husband suffered a mild stroke two weeks ago. Charlene Marshall disclosed the stroke Monday outside the courtroom where her husband is on trial on charges of looting his late mother's $198 million estate.

August 12th, 2009 WASHINGTON - A new investigational, orally inhaled therapy has been found effective in treating migraines, according to researchers. The research team from Thomas Jefferson University Hospital in Philadelphia, Pennsylvania have shown that LEVADEX provided pain relief in 30 minutes and sustained relief for 48 hours.

April 29th, 2009 WASHINGTON - Researchers have found a potential target for developing new treatment for acute migraine attacks. The new research by Addex Pharmaceuticals showed that targeting glutamate receptor 'mGluR5', the most common neurotransmitter in the brain, could prevent migraines.

June 2nd, 2009 WASHINGTON - Half of mini-strokes lead to major stroke within 24 hours of the first event, a new research has found. The research has been published in the June 2, 2009, print issue of Neurology, the medical journal of the American Academy of Neurology.

July 21st, 2009 Contrave is an experimental weight-loss drug developed by Orexigen Therapeutics Inc. It has been shown to significantly aid weight loss in three late-stage clinical trials according to Associated Press reports.